News|Articles|March 18, 2025

Pharma Pulse 3/18/25: Modernizing Patient Recruitment, OTC Approaches for Managing Menopause Symptoms & more

The latest news for pharma industry insiders.

Modernizing Patient Recruitment

In this video interview, Cameron Breze, product manager, Inovalon, discusses current challenges with patient recruitment and how a combination of technology and manual effort can help improve efficiency.

Dietary, Lifestyle, and OTC Approaches for Managing Symptoms of Menopause

Panelists discuss how health care professionals recommend lifestyle modifications, dietary changes, and OTC products to manage menopause symptoms, focusing on exercise, nutrition, stress reduction, and targeted supplements to support overall well-being during this transitional period.

Novo Reinstated by UK Pharma Body After Two-Year Suspension

Novo Nordisk A/S is a member of the UK pharmaceutical industry association again, following a two-year suspension for breaching the country’s code of practice for drugmakers.

GoodRx Appoints Aaron Crittenden as President of Rx Marketplace and Scott Pope, PharmD, as Chief Pharmacy Officer and Head of Clinical Engagement

GoodRx has announced the appointment of Aaron Crittenden as President of Rx Marketplace and Scott Pope, PharmD, as Chief Pharmacy Officer and Head of Clinical Engagement, effective immediately.

Todd Foster on LinkedIn

This is pretty cool. My first Pharma Exec article. Any guess what it's about? Spoiler alert in the hashtags.
#datamanagement #biopharma #emergingbiopharma #datastrategy

Have news you want us to share in Pharma Pulse? Reach out to Editor Miranda Schmalfuhs


Related to this article

Pharmaceutical Executive Daily
FDA approves Ultragenyx's Fayuvi as the first treatment for Sanfilippo syndrome type A, Lisata Therapeutics acquires Marea Therapeutics as mAbxience partners with Sandoz on a hemophilia A biosimilar, and Joe Cunningham argues that executive drug-pricing deals alone won't fix costs.
Former U.S. Representative Joe Cunningham (D-SC), spokesperson, Pharmaceutical Reform Alliance.
Former U.S. Representative Joe Cunningham (D-SC), spokesperson, Pharmaceutical Reform Alliance. dismisses the pharmaceutical industry's innovation argument against MFN pricing.